Cyclosporin A and tacrolimus reduce T-cell polyfunctionality but not interferon-gamma responses directed at cytomegalovirus

Fuhrmann, S, Lachmann, R, Streitz, M, Hetzer, R, Volk, H D, Lehmkuhl, H and Kern, F (2012) Cyclosporin A and tacrolimus reduce T-cell polyfunctionality but not interferon-gamma responses directed at cytomegalovirus. Immunology, 136 (4). pp. 408-413. ISSN 0019-2805

Full text not available from this repository.

Abstract

Cytomegalovirus (CMV) -specific immunity is often estimated by the number of in vitro CMV antigen-inducible interferon-gamma-positive (IFN-gamma(+) ) T cells. However, recent work indicates that simultaneous production of IFN-gamma, tumour necrosis factor-alpha (TNF-alpha) and interleukin-2 (IL-2) (referred to as 'polyfunctionality') is more relevant for anti-viral protection. Here, we compared polyfunctionality of CMV-specific T cells (pp65 and IE-1 proteins) in 23 solid-organ transplant patients and seven healthy controls by flow cytometry. The proportions of TNF-alpha(+) /IFN-gamma(+) /IL-2 cells among the activated cells were significantly reduced in transplant patients but not the frequencies of IFN-gamma(+) CD8(+) T cells. Immunosuppression reduces polyfunctionality, which reflects the increased infection risk in this patient group.

Item Type: Article
Keywords: Adolescent; Adult; CD8-Positive T-Lymphocytes/drug effects/*immunology/metabolism Cyclosporine/*pharmacology Cytomegalovirus/*immunology Cytomegalovirus Infections/*immunology Female Humans Immunosuppressive Agents/*pharmacology Interferon-gamma/*biosynthesis Interleukin-2/biosynthesis Lymphocyte Activation Male Middle Aged Organ Transplantation Tacrolimus/*pharmacology Tumor Necrosis Factor-alpha/biosynthesis Young Adult
Schools and Departments: Brighton and Sussex Medical School > Clinical and Experimental Medicine
Subjects: Q Science > QR Microbiology > QR0180 Immunology
Depositing User: Florian Kern
Date Deposited: 22 Oct 2012 10:35
Last Modified: 22 Oct 2012 10:35
URI: http://srodev.sussex.ac.uk/id/eprint/41298
📧 Request an update